Company intelligence / Profile preview

Marathon B2B

Northbrook, Illinois, USAmarathonb2b.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Marathon Pharmaceuticals developed and commercialized drugs for rare diseases. Its main product was deflazacort (Emflaza), approved by FDA for Duchenne muscular dystrophy. The company was criticized over pricing practices and sold its key asset to PTC Therapeutics before winding down operations in 2017.

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Patient advocacy groups such as NORD during commercialization efforts.

Beyond the preview

Go deeper on Marathon B2B.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marathon B2B.

Explore the full profile